In 2018, CureDuchenne was the only Duchenne-focused organization to invest in Avidity Biosciences, recognizing the potential of their novel RNA-targeting approach for individuals with Duchenne muscular dystrophy long before it reached clinical trials. […]
Updated: December 4, 2025 From Belief to Breakthrough: Celebrating Avidity’s Potential Acquisition by Novartis In 2018, CureDuchenne made a bold investment in a promising company with an idea that could […]
Avidity Biosciences, which received early funding from CureDuchenne, announced positive initial data from their EXPLORE44 Trial for individuals with Duchenne amenable to skipping exon 44. Their experimental exon-skipping agent, AOC […]
A Clinical Trial Investigating the Potential for AOC 1044 to Treat Individuals with DMD Mutations Amenable to Exon 44 Skipping Join Cure Duchenne’s webinar as we welcome Kelly DiTrapani and […]
